Publications

21

Dec, 2016

Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?

 

Authors: Bernays S, Paparini S, Seeley J, Namukwaya Kihika S, Gibb D, Rhodes T.

Published inBMJ Open. 2017;7(2):e012934

Abstract: A qualitative study of the BREATHER (PENTA 16) randomised clinical trial, which compared virological control of Short Cycle Therapy (SCT) (5 days on: 2 days off ) with continuous efavirenz (EFV)-based antiretroviral therapy (CT) in children and young people (aged 8–24) living with HIV with viral load <50 c/mL to examine adaptation, acceptability and experience of SCT to inform intervention development

Read

20

Nov, 2016

Tuberculosis in HIV-infected children in Europe, Thailand and Brazil: paediatric TB-HIV EuroCoord study

 

Authors: Turkova A, Chappell E, Chalermpantmetagul S, et al.

Published in: Int J Tuberc Lung Dis 2016, 20:1448-1456.

Read

11

Nov, 2016

Interventions to improve treatment, retention and survival outcomes for adolescents with perinatal HIV-1 in high- and middle-income countries: Moving on up.

 

Authors: Judd A, Sohn A, Collins J.

Published in: Current Opinion in HIV and AIDS 2016; 11(5): 477-486

Read

8

Nov, 2016

Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children – a EuroCoord-CHAIN-EPPICC joint project.

 

Published in: BMC Infectious Diseases, in press.

Read

14

Sep, 2016

Higher rates of triple class virologic failure in perinatally HIV-infected teenagers compared to heterosexually infected young adults in Europe. 

 

Authors: Judd A, Lodwick R, Noguera-Julian A, Gibb DM, Butler K, Costagliola D, Sabin C, van Sighem A, Ledergerber B, Torti C, Mocroft A, Podzamczer D, Dorrucci M, De Wit S, Obel N, Dabis F, Cozzi-Lepri A, García F, Brockmeyer NH, Warszawski J, Gonzalez-Tome MI, Mussini C, Touloumi G, Zangerle R, Ghosn J, Castagna A, Fätkenheuer G, Stephan C, Meyer L, Campbell MA, Chene G, Phillips A; Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Published in: HIV Medicine, in press.

Read

4

Aug, 2016

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women

 

Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al.

Published in: Front Pharmacol. 2016; 7:239.

Abstract: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women.

Read

31

Jul, 2016

Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman

 

Authors: Schalkwijk S, Feiterna-Sperling C, Weizsacker K, et al.

Published in: Aids. 2016; 30(12):1999-2001

24

Jun, 2016

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents – a multiregion analysis from Southern Africa, West Africa, and Europe.

 

Authors: Schomaker M, Leroy V, Wolfs T, Technau KG, Renner L, Judd A, et al. on behalf of the IeDEA West and Southern Africa regional collaborations and COHERE in EuroCoord.

Published in: International Journal of Epidemiology – in press.

Read

1

Jun, 2016

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial

 

Author: Butler K, Inshaw J, Ford D, et al.

Published in:  Health Technol Assess2016;20(49):1-108.

Abstract: The trial showed that short-cycle antiretroviral therapy was not inferior to continuous therapy in suppressing human immunodeficiency viral load in young people taking efavirenz-based first-line therapy and a viral load of < 50 copies/ml, with similar resistance, safety and inflammatory marker profiles.

Read

1

Jun, 2016

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

 

Author: The BREATHER (PENTA 16) Trial Group

Published inLancet HIV. 2016;3(9):e421-430

Abstract: For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).

Read